Developing a new treatment for Alzheimer's Disease
Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease
['FUNDING_SBIR_2'] · VIROGENICS, INC. · NIH-11008209
This study is testing a new drug called CMS121 that could help improve memory and thinking skills in people with Alzheimer's Disease, offering a different approach than current treatments, and it might make a real difference if it works well in trials.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIROGENICS, INC. (nih funded) |
| Locations | 1 site (DEL MAR, UNITED STATES) |
| Trial ID | NIH-11008209 on ClinicalTrials.gov |
What this research studies
This research focuses on CMS121, a novel drug candidate for Alzheimer's Disease (AD) that aims to improve memory and executive function in patients. Unlike existing treatments that primarily target amyloid plaques, CMS121 interacts with different biological targets to potentially modify the disease's progression. The drug has shown promise in preclinical models by preventing and reversing cognitive decline associated with AD. Patients may benefit from this innovative approach if the drug proves effective in clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's Disease or exhibit symptoms of age-related cognitive decline.
Not a fit: Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's Disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves cognitive function and quality of life for individuals with Alzheimer's Disease.
How similar studies have performed: While many Alzheimer's treatments have failed, the novel approach of CMS121 offers a unique perspective that has not been extensively tested in clinical settings, making it a potentially groundbreaking effort.
Where this research is happening
DEL MAR, UNITED STATES
- VIROGENICS, INC. — DEL MAR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RASCHKE, WILLIAM C — VIROGENICS, INC.
- Study coordinator: RASCHKE, WILLIAM C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome